Favoni Corporate Center, LLC is working with Tranzon Metrolina to promote adeveloper close-out sale of 3 adjoining land parcels and is offeringnon-qualifying owner financing to buyers."Owner financing makes this auctionan incredible opportunity for investors and developers," says Joe Jackson,Managing Partner of Tranzon Metrolina."These lots will be sold at a sealedbid auction - a form of auction where bidders submit one bid in a concealedfashion. Tranzon Metrolina, headquartered in Concord, North Carolina (NCAF8415) is afull-service real estate auction company and a member of Tranzon L.L.C.Withover 20 independently owned offices from coast to coast, the member companiesof Tranzon auctioned more than 700 properties last year and have conductedauctions in 46 states and the District of Columbia.Tranzon professionalsspecialize in providing real estate, business asset and liquidation auctionand accelerated marketing services to corporations, financial institutions,trustees, individuals and estates throughout the U.S.SOURCETranzon MetrolinaJoe Jackson, 1-877-772-6966, +1-704-634-5150,. REDWOOD CITY, Calif., May 5 /PRNewswire/ -- Ingenuity Systems, the leadingprovider of information solutions for life science researchers, todayannounced a multi-year agreement with AstraZeneca.AstraZeneca plans toexpand the utilization of IPA in its research and target discovery programs togain deeper domain knowledge of disease-related pathways and targets.As part of the agreement, AstraZeneca researchers plan to leverage thepowerful analysis application, to build biological models, analyze data, andreliably answer sophisticated biological and chemical questions in theireffort to identify and progress promising targets.Results generated in IPA can be easily shared across teams, so researchers canwork together to make more informed decisions. "IPA is an extensive platformfor understanding and communicating the dynamic behaviors of complexbiological systems," said Dr Ian Dix, Principal Informatics Scientist,AstraZeneca. "IPA can support a wide range of research objectives across ourtarget and biomarker discovery programs - such as providing insight intotarget efficacy, drugability and, increasingly, toxicity.The richness andcontextual nature of the content is important for us because it provides adetailed view of the molecular basis of disease, critical in the drugdiscovery decision-making process.""We are pleased to enhance and extend our relationship with AstraZeneca and tocontinue to provide AstraZeneca's researchers with greater workflow anddecision support," said Sean Scott, SVP of Sales and Operations at IngenuitySystems. "IPA continues to deliver value to AstraZeneca researchers byproviding the right capabilities and content to understand biological systemsand uncover insights that impact business decisions."About Ingenuity Pathways AnalysisIngenuity Pathways Analysis (IPA) is an all-in-one software application thatenables researchers to model, analyze, and understand the complex biologicaland chemical systems at the core of life science research.IPA's searchcapabilities provide users with access to the highest quality detail-richknowledge available on genes, drugs, chemicals, protein families, cellular anddisease processes, and signaling and metabolic pathways.

IPA supports analysisof data from all experimental platforms, and is used at all stages of the drugdiscovery and development process, including target identification andvalidation, biomarker discovery, molecular toxicology, metabolomics, andpharmacogenomics.IPA has been broadly adopted and cited in hundreds ofpeer-reviewed journals.About Ingenuity Systems(R)Ingenuity Systems is a leading provider of information solutions and customservices for life science researchers, computational biologists andbioinformaticists, and life science industry suppliers. Our long-term focus oninnovation in semantic search has allowed us to create groundbreakingtechnologies that have one common goal -- to generate maximum value from alltypes of biological and chemical knowledge. Ingenuity offerings leverage theIngenuity Knowledge Base, which contains uniquely structured literaturefindings that allow scientists to ask complex biological questions and gainrapid insight into their experimental data or systems of interest. Today,Ingenuity's solutions are used by thousands of researchers at hundreds ofleading pharmaceutical, biotechnology, academic, and government researchinstitutions worldwide.

For more information visit: AstraZeneca AstraZeneca is a major international healthcare business engaged in research,development, manufacturing and marketing of meaningful prescription medicinesand supplier for healthcare services. AstraZeneca is one of the world'sleading pharmaceutical companies with healthcare sales of US$ 31.6 billion andis a leader in gastrointestinal, cardiovascular, neuroscience, respiratory,oncology and infectious disease medicines.For more information visit: SystemsHeidi Bullock, Director, Marketing of Ingenuity Systems, +1-650-381-5150. * Second quarter revenues of $164.8 million declined 13.0% year over year, or4.5% on a constant currency basis.* Operating income, excluding amortization expense, totaled $31.3 million,compared to $39.0 million in the prior year period.* Sirona reaffirms Fiscal Year 2009 guidance.LONG ISLAND CITY, N.Y.--(Business Wire)--Sirona (Nasdaq: SIRO), a leading global manufacturer of technologicallyadvanced, high quality dental equipment, today reported its financial resultsfor the quarter and six months ended March 31, 2009 Second Quarter Fiscal 2009 vs. Second Quarter Fiscal 2008 Financial ResultsRevenue was $164.8 million, a decrease of $24.7 million or 13.0% (down 4.5%constant currency), with growth rates for the Company's business segments asfollows: CAD/CAM declined 5.8% (flat constant currency), Treatment Centersdeclined 16.0% (down 4.2% constant currency), Instruments declined 16.2% (down4.3% constant currency), and Imaging Systems declined 17.9% (down 10.5% constantcurrency) Revenue in the United States decreased by 1.1%.

Outside the UnitedStates, revenue decreased 18.0% (down 6.1% constant currency), with mixedresults among the various countries. Positive revenue growth in Germany, Japanand Australia, was more than offset by declines, particularly in Europeancountries. Gross profit declined by $6.1 million to $80.3 million, down 7.0%. Gross profitmargins expanded 3.1%, mainly due to lower deal related amortization and productmix. Second quarter 2009 operating income excluding amortization expense was $31.3million (operating income of $13.7 million plus amortization expense of $17.6million), compared to $39.0 million (operating income of $16.2 million plusamortization expense of $22.8 million) in the prior year.

Second quarter 2009results included a $2.8 million restructuring expense. Net income for the second quarter of 2009 was $0.6 million, or $0.01 per dilutedshare, compared to $10.9 million, or $0.20 per diluted share, for the secondquarter of 2008. Second quarter 2009 earnings per share included $0.23 ofamortization and depreciation expense attributable to the write-up in value ofassets due to purchase accounting, a loss of $0.05 related to the revaluation ofthe Patterson exclusivity fee, a loss of $0.03 resulting from the revaluation ofshort-term intra-group loans, and a $0.04 restructuring charge. For the secondquarter of 2008, earnings per share included $0.28 of amortization anddepreciation expense attributable to the write-up in value of assets due topurchase accounting, a gain of $0.085 related to the revaluation of thePatterson exclusivity fee and a $0.056 gain resulting from the revaluation ofshort-term intragroup loans.